Summary: Cigna Healthcare modified its coverage policy for peripheral nerve destruction for pain conditions (Policy 0525), effective May 16, 2026. Here's what billing teams need to do before that date.
This update to the Cigna Healthcare peripheral nerve destruction coverage policy affects practices billing for nerve ablation and neurolytic procedures used to manage chronic and acute pain. The policy document does not list specific CPT or HCPCS codes in the data available to us — we address that directly in the Affected Codes section below. If your practice bills Cigna for any peripheral nerve destruction procedures, review your prior authorization workflows and medical necessity documentation before May 16, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Peripheral Nerve Destruction for Pain Conditions |
| Policy Code | 0525 |
| Change Type | Modified |
| Effective Date | May 16, 2026 |
| Impact Level | High |
| Specialties Affected | Pain management, anesthesiology, neurology, orthopedic surgery, interventional radiology |
| Key Action | Audit your peripheral nerve destruction claims against updated medical necessity criteria before May 16, 2026 |
Cigna Peripheral Nerve Destruction Coverage Criteria and Medical Necessity Requirements 2026
Peripheral nerve destruction covers a range of procedures designed to interrupt pain signals by ablating or chemically destroying nerve tissue. These procedures span radiofrequency ablation, cryoablation, chemical neurolysis, and other neurolytic techniques applied to peripheral nerves — not the spinal cord or central nervous system.
Cigna's coverage policy for these procedures has always been tight on medical necessity. Cigna typically requires documented failure of conservative treatments before approving peripheral nerve destruction. That means your records need to show the patient has already tried — and not responded to — physical therapy, oral medications, or other non-interventional pain management approaches.
The modification effective May 16, 2026 means Cigna has updated the specific criteria, language, or covered indications within Policy 0525. Because the published policy document does not surface the line-by-line changes in the data available here, the safest move is to pull the full policy text directly from Cigna's provider portal or from the source document at PayerPolicy before billing any peripheral nerve destruction claim to Cigna after that effective date.
Prior authorization is almost certainly required for these procedures under Cigna plans. Peripheral nerve destruction is not a low-scrutiny service — Cigna treats it as a high-cost interventional procedure and has historically required prior auth across most plan types. Confirm your prior authorization requirements with Cigna's provider line or portal before scheduling the procedure, not after.
The reimbursement exposure here is real. A denied claim for peripheral nerve destruction represents a significant revenue hit — these are not low-dollar codes. Getting the medical necessity documentation wrong means fighting a claim denial on a procedure that may cost thousands of dollars to perform.
Cigna Peripheral Nerve Destruction Exclusions and Non-Covered Indications
Cigna has historically drawn hard lines around peripheral nerve destruction procedures it considers experimental or investigational. Several techniques in this space lack the peer-reviewed clinical evidence Cigna requires for covered status.
Procedures Cigna has previously classified as experimental or not medically necessary in this category include nerve destruction for certain headache syndromes, occipital nerve ablation for indications outside of specific diagnostic criteria, and cryoablation of peripheral nerves where long-term outcomes data is insufficient. Chemical neurolysis for non-cancer pain has also faced coverage challenges under some Cigna plans.
Because the May 16, 2026 modification may have shifted any of these exclusions — in either direction — you cannot rely on what Cigna covered or excluded last year. Pull the updated Policy 0525 text and compare it against your current charge capture. If you are not sure how a specific indication maps to the revised criteria, talk to your compliance officer before the effective date.
Coverage Indications at a Glance
The policy data provided does not include a detailed, indication-level breakdown of covered versus non-covered conditions under the May 16, 2026 modification. The table below reflects Cigna's general historical coverage framework for peripheral nerve destruction. Treat this as a starting framework — not a substitute for the actual updated policy text.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Peripheral nerve destruction for chronic pain — post-conservative treatment failure | Generally Covered (criteria apply) | See Affected Codes section | Medical necessity documentation required; prior auth likely required |
| Radiofrequency ablation of peripheral nerves for documented pain syndromes | Generally Covered (criteria apply) | See Affected Codes section | Specific diagnostic criteria apply; verify against updated 0525 text |
| Cryoablation of peripheral nerves | Historically variable — verify under updated policy | See Affected Codes section | Coverage has varied by indication and plan type |
| Chemical neurolysis (non-cancer pain) | Often Not Covered or Experimental | See Affected Codes section | Check updated 0525 for any status changes effective May 16, 2026 |
| Peripheral nerve destruction for headache syndromes | Often Not Covered or Experimental | See Affected Codes section | Occipital nerve ablation scrutinized; verify specific diagnostic criteria |
| Peripheral nerve destruction where conservative care was not attempted | Not Covered | N/A | Failure of conservative treatment is a standard prerequisite |
Pull the full updated Policy 0525 text to confirm each row. Any of these statuses may have shifted with this modification.
Cigna Peripheral Nerve Destruction Billing Guidelines and Action Items 2026
Peripheral nerve destruction billing under Cigna requires clean documentation from the first touch. Here is what your billing team needs to do before and after May 16, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the full Policy 0525 text before May 16, 2026. Access it directly through Cigna's provider portal or at the PayerPolicy source link. Read the actual coverage criteria — do not rely on how you billed these procedures last year. Policies like this one get modified precisely because Cigna wants to tighten or clarify what they will and will not pay for. |
| 2 | Confirm prior authorization requirements for every peripheral nerve destruction procedure. Contact Cigna's provider services line or check NaviMedix/Cigna's auth portal. Prior authorization requirements can differ by plan type — commercial, Medicare Advantage, and Cigna Connect plans may each have different auth thresholds. Know which plans require auth before you schedule. |
| 3 | Audit your medical necessity documentation templates. Cigna requires evidence of conservative treatment failure before approving peripheral nerve destruction. Your documentation should explicitly show what was tried, for how long, and why it failed. A vague note that the patient has chronic pain is not enough. Update your templates to capture the specific prior treatment history Cigna needs to see. |
| 4 | Check your charge capture for any peripheral nerve destruction codes currently in your chargemaster. Because this policy was modified — not newly created — there may be specific criteria changes that affect codes you are already billing. If your practice bills radiofrequency ablation, cryoablation, or chemical neurolysis codes to Cigna, cross-reference each one against the updated 0525 criteria before submitting claims dated on or after May 16, 2026. |
| 5 | Train your prior auth and clinical documentation teams together. The most common reason a peripheral nerve destruction claim denial happens is a mismatch between what the clinical team documented and what the billing team submitted. The clinical note has to support the specific medical necessity criteria in the coverage policy — not just describe the procedure. Run a joint session with your clinical and billing staff before the effective date to close that gap. |
| 6 | Flag pending claims and scheduled procedures near the May 16, 2026 transition. If you have procedures scheduled in the window around the effective date, confirm whether the current or updated policy criteria apply. Cigna typically applies the policy in effect on the date of service — but verify this with your Cigna provider rep for procedures scheduled right at the transition. |
| 7 | Talk to your compliance officer if your practice has high Cigna volume for these procedures. This is a high-dollar, high-scrutiny category. If peripheral nerve destruction represents meaningful revenue in your Cigna book of business, the compliance and financial exposure from getting the updated billing guidelines wrong is significant. Do not wait until you see a claim denial pattern to act. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Peripheral Nerve Destruction Under Cigna Policy 0525
The policy data available for this modification does not include a specific list of CPT, HCPCS, or ICD-10 codes. We do not fabricate codes — so we are not listing them here.
This is important for your billing team to understand. The absence of a published code list in the available data does not mean codes are not specified in the actual policy document. It means you need to access the full Policy 0525 text directly to get the complete code list.
Access the full policy here: https://app.payerpolicy.org/p/cigna/mm_0525_coveragepositioncriteria_peripheral_nerve_destruction
When you pull the policy, look specifically for:
- CPT codes in the 64600–64640 range, which cover destruction of peripheral nerves and branches
- Any radiofrequency ablation codes that Cigna specifically designates as covered versus experimental under this policy
- Cryoablation codes and their coverage status
- ICD-10-CM diagnosis codes Cigna accepts as supporting medical necessity for covered indications
Build your internal code reference table from the actual Policy 0525 document. Then verify it against your current chargemaster before May 16, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.